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ABSTRACT 
Extended release formulations are becoming more popular day by day for the delivery of non-steroidal anti-inflammatory drugs 
(NSAIDs) because of their ability to maintain optimal and therapeutically effective drug levels for prolonged duration with the 
reduction in dosing frequency and side effects associated with NSAIDs. Etodolac is a non-steroidal anti-inflammatory drug. It is an 
inhibitor of cycloxygenase which belongs to the pyranocarboxylic acid group, which is effective in treating fever, pain, and 
inflammation in the body, which is degraded in the stomach. In the present study, a suitable particulate system of Etodolac has been 
developed, by ionotropic gelation method for sustained release that would result in prolonged clinical efficacy, reduced frequency of 
administration and lesser side effects. Micro beads were fabricated with and without using guar gum as polymer and were 
characterized for particle size and size distribution analysis, flow properties, loose surface crystal study, entrapment efficiency, 
swelling ratio, percentage yield and drug content uniformity and in-vitro drug release. It was found that the particle size distribution 
of both formulations was varied within a narrow size range. Drug leaching (14.98 % ± 0.118) was more with presence of guar gum. 
Entrapment efficiency was retarded with the presence of guar gum. Swelling ratio (53.49 ± 1.874) advocated that guar gum 
incorporated microbeads swelled more to behave as a matrix for controlled drug delivery. Establishment of highly viscous dispersion 
with the incorporation of polymer led to high percentage yield (49.35% ± 01.230). Drug release data was fitted to various kinetic 
models and indicated that the mechanism was according to peppas model. The study discovered that the microbeads of Etodolac 
could be efficaciously formulated by ionotropic gelation technique with sustained release characteristics.  
Keywords: NSAIDs, Alginate beads, cycloxygenase, Ionotropic gelation, Guar gum. 
 
Article Info 
Received Feb 13, 2017; Review Completed Feb 25, 2017; Accepted March 13, 2017; Available online March 15, 2017 
Cite this article as: 
Kapoor D, Patel M, Vyas RB, Lad C, Gujral G, Fabrication and characterization of non steroidal anti-inflammatory alginate beads for 
sustained release using natural polymer, Journal of Drug Delivery and Therapeutics. 2017; 7(2):77-80.  
DOI: http://dx.doi.org/10.22270/jddt.v7i2.1401  
*Address for Correspondence  
Dr. Devesh Kapoor, Dr. Dayaram Patel Pharmacy College, Sardar baug, Station Road, Bardoli, Dist – Surat, Gujarat, India, Pin-
394601, E-mail: dev7200@gmail.com, Contact Info - +91-7874223242 
________________________________________________________________________________________________ 
 
INTRODUCTION: 
Numerous techniques were reported previously for 
preparation of sustained release pharmaceutical 
formulations such as coating an osmotically active drug 
core with a semi-permeable membrane, encapsulation of 
beads, pellets or tablets with different levels and types of 
diffusion barriers. However use of sophisticated 
equipment in their formulation, number of critical 
manufacturing process variables, difficulties in scale-up 
and use of skilled manpower had limited their routine 
use in the industry. Gastric emptying of a drug is a 
complex process that makes in vivo performance of drug 
delivery systems uncertain; however, the floating or 
hydro dynamically controlled drug delivery systems 
namely, floating microspheres, micro beads, and 
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microcapsules are useful in overcoming such 
uncertainty. Micro beads are small, solid and free 
flowing particulate carriers containing dispersed drug 
particles either in solution or crystalline form that allows 
a sustained release or multiple release profiles compared 
with the monolithic formulations. They release the 
active ingredients through a double mechanism: 
diffusion and/or biodegradation of the polymer. The 
cross-linked microbeads, depending on the biodegra-
dability and biocompatibility, can be administered as 
long lasting medications. The use of coating substances 
which can dissolve either in different areas of the 
gastrointestinal tract (depending on pH and/or the 
enzymes present) or after a preset time (depending on 
the thickness) allows coated microbeads to be used both 
in a space- and- time focused manner. 
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Etodolac, 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b] 
indole-1-il)acetic acid is an example of non-steroidal 
anti-inflammatory drugs (NSAIDs). It is especially 
beneficial in treatment of chronic conditions of arthritis, 
osteoarthritis and similar rheumatism diseases. Etodolac 
is a medicine with a short elimination half-life of 8 h and 
low and pH-dependent solubility between pH 3 to 
7.Thus in order to maintain the effective plasma levels 
of the drug, its frequent administration are needed which 
would in turn lead to NSAID-related side effects on 
gastro-intestinal (GI) system. Also once-a-day sustained 
action medications for drug molecules with short half-
lives typically like Etodolac present formulation 
problems because of their relatively short residence time 
into GI tract before elimination.
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Natural  polymers particularly  in  the  form  of  
microspheres,  have  an  important  role  in  the  before  
they  will  have widespread  use  in  clinical  situations.  
Among  these  issues  are  better  understanding  of  the  
kinetics  of  drug  release; more  effective  ways  to  
control  burst  phenomena;  greater  understanding  of  
drug polymer  interactions and their effect on shelf life  
stability;  additional  animal  studies  to determine  local  
tissue response, biodegradation rates, and  metabolic 
rate; and, most importantly, as it relates to cancer 
chemotherapy, well designed Clinical  studies  to assess 
efficacy in  relation to current therapies. In the area of 
drug targeting, there needs to be continuing emphasis  
on understanding the phagocytes and cell receptors. Gua
r gum is a natural nonionic polysaccharide being used as 
drug carrier for colonic delivery system due to its release 
retarding property and susceptibility to microbial degra-
dation. Guar gum is derived from the seeds of cyamposis 
tetragonolobus. Guar gum is hydrophilic in nature, 
swells in cold water and forming viscous colloidal 
dispersions or sols. This  gelling  property  retards  
release of  the  drug  from  the  dosage  form  as  well  as 
it is susceptible to degradation in the colonic environ-
ment.
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The present paper pronounces the fabrication of 
microbeads of Etodolac by ionic gelation with and 
without guargum as polymer, and studies various pre 
and pro evaluation parameters to obtain the required 
release rate of Etodolac microbeads. 
MATERIALS: 
Etodolac was a gift sample from creative organics, 
Hyderabad. Guar gum, Methanol, Sodium alginate, 
Calcium chloride, and Sodium hydroxide were USP/NF 
quality and were procured from S.D. Fine Chem ltd, 
Mumbai, India). All other chemicals used throughout the 
study were of analytical grade.  
METHODS  
Fabrication of etodolac alginate microbeads:  
Alginate microbeads, each containing 200 mg Etodolac 
were fabricated by Ionotropic gelation method. The 
symphony of an assortment of formulations of the 
microbeads with their codes is listed in Table 1. 
Formulation F2 was prepared with guar gum, while F1 
was without maize gum. Active pharmaceutical 
ingredient Etodalac was added to slurries of 2.5% w/v 
sodium alginate. Both the slurries were independently 
dispersed thoroughly using mechanical stirrer for 15 
minutes and taken in 10 ml hypodermic needle fitted 
with a 20 gauge needle. The mixtures were added drop 
wise to calcium chloride solution (3% w/v), and stirred 
at 200 rpm. The gelation time of 1 hour was allowed to 
complete the curing reaction and to fabricate spherical 
and rigid microbeads. The beads were unruffled by 
decantation, washed 3 times with distilled water and 
dried at 60
o
 C for 2 hours in a hot air oven.
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Table 1: Fabrication of etodolac alginate microbeads:  
Formulation 
code  
  
 
API 
(mg)  
 
 
Sodium alginate 
(% w/v) 
Calcium chloride 
(% w/v)  
 
Maize starch 
(mg) 
Curing time 
(min) 
F1 200 2.7 5 NIL 25 
F2 200 2.7 5 200 25 
 
Characterization of etodolac alginate microbeads:  
Physical characterisation:  
The particle sizes of the microbeads were determined 
using optical microscopy method. The microbeads were 
mounted in light liquid paraffin and the diameters of 100 
particles were measured by means of an optical 
microscope with calibrated micrometers and the mean 
diameter was calculated. 
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Size determination of microbeads: 
Particle size was determined by using a laser diffraction 
particle size analyzer [Cilas 1064L, Orleans, France]. 
Microbeads were suspended in the chamber of the 
particle size analyzer containing distilled water, and the 
particle size was determined using the software provided 
by the manufacturer. 
6
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Drug entrapment efficiency: 
It is the quantity of the drug retained by the system. 
There are two types of methods to calculate this, one is 
direct method and other is indirect. Here the direct 
method was used to calculate the entrapment efficiency. 
The calculated amount of the microbeads were crushed 
and digested with acetone for 2 hours with continuously 
shaking. The solution was stirred on a magnetic stirrer 
for 15 min, filtered and 1ml of the filtrate was diluted 
using phosphate buffer (pH 6.8) and analysed 
spectrophotometrically at 274nm. The drug entrapment 
efficiency was calculated as per the following formula. 
7
 
The % entrapped drug was calculated by using 
following formula: 
% entrapped drug = Total amount of drug found in 
formulation/ Total amount of drug used in formulation× 
100 
Swelling ratio: 
Swelling properties of the drug loaded microbeads were 
determined at pH range 6.8. Thirty dried beads were 
placed in phosphate buffer (pH 6.8) and allowed to 
swell at 37
o
 C. After 2 hour interval, the equilibrium 
swollen beads were observed and measured by optical 
microscopy. Swelling ratio was determined from the 
following relation: 
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Swelling ratio = (Mean diameter at time t- initial 
diameter)/Initial diameter of beads × 100 
% yield: 
The percentage yield of micro beads has been calculated 
using following equation. 
9
 
Percentage yield of microbeads = Total yield of 
microbeads/Total weight of polymer × 100 
In-vitro drug release: 
The in-vitro drug release behavior of the microbeads 
was evaluated in phosphate buffer (pH 6.8). The basket 
method was used to carry out the dissolution tests. The 
basket position was set at 2.5 cm from the bottom of the 
flask and speed was adjusted to 75 rpm. The dissolution 
studies were carried out in 900 ml phosphate buffer 
maintained at 37 ± 0.5°C. Microbeads containing 200 
mg of the drug were employed in each case. Aliquots of 
5ml were withdrawn and immediately replaced the 
dissolution medium to preserve a constant volume of 
900 ml. Stirring was continued for 6 hours and speed 
was increased to 250rpm for the last 20 minutes in order 
to estimate the 100 % release point. The samples were 
filtered and absorbance was determined at 274 nm using 
UV-Visible spectrophotometer against an appropriate 
buffer as a blank. 
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RESULTS AND DISCUSSION  
Particle size and size distribution analysis:  
It was established that the particle size distribution of 
both formulations was varied within a narrow size range 
as shown in Table 2. But the mean particle sizes were 
dissimilar among these formulations. The outcome 
indicated that the proportional boost in the mean particle 
size of microbeads augmented with the existence of guar 
gum in the formulation. This could be certified to the 
formation of large droplets during addition of polymer 
solution to the gelling agent. 
  
Table 2: Average mean diameter of the etodoloac alginate beads 
Contents F1 F2 
Surface mean diameter (μm) 415.48 ± 0.122 438.71 ± 0.208 
Volumer mean diameter 414.44±2.33 424.90±0.22 
Surface length mean diameter 417.28±2.56 428.45±3.21 
Volume surface mean diameter 424.76±8.77 435.56±1.87 
Weight moment mean diameter 430.11±1.23 434.98±0.99 
 
Entrapment efficiency:  
The amount of drug entrapped was more in F1 (38.11% 
± 0.11) that does not contain guar gum when compared 
to F2 (24.55% ± 1.241).This may be attributed to lesser 
number of binding sites of alginate for Ca2
+
 ions 
resulting in the formulation of a less dense gel 
membrane which, in turn, increases influx of Ca2
+ 
ions 
leading to diminish in drug entrapment efficiency.  
Flow properties:  
The results presented in Table 3 showed that F2 which 
has the polymer incorporated is more freely flowing than 
F1 which be deficient in polymer. Thus, the microbeads 
if tabletted or encapsulated, requires fewer amount of 
lubricants and ensures small production cost leading to 
its practicability for large scale production.  
 
Table 3: Values for different flow properties 
parameters for F1 and F2 
Properties F1 F2 
Angle of repose 25.78º±2.33 29.11º±1.87 
Bulk density 0.42±3.456 0.48±1.987 
Tapped density 0.55±4.21 0.48±0.256 
Carr’s index 22.45±1.89 9.78±2.22 
Hausners’s ratio 1.29±0.99 1.10±2.45 
 
Swelling ratio and percentage yield of microbeads:  
The mean diameter of swelling beads to dried beads was 
found to be greater for formulation prepared by utilizing 
maize starch polymer F2 (53.49 ± 1.874), compared to 
F1 (55.27 ± 0.139) suggesting that guar gum microbeads 
may begin to puff up more and act as matrices for 
controlled release of incorporated drug. The percentage 
yield was found to be elevated for the formulation 
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equipped using guar gum polymer F2 (49.35% ± 01.230) 
when compared to F1 (43.17 ± 1.132 %). This could be 
due to the configuration of elevated viscous polymer 
dispersion which is not lost during manufacturing 
process. 
In-vitro drug release: 
The drug release kinetics is presented in Table 4 and 
follows a complex order drug release. The correlation 
co-efficient (r2 value = 0.966) indicates that the release 
mechanism is diffusion and the n value of Peppas model 
(0.339) indicates that the mechanism of drug release 
follows Fickian diffusion. This suggests that drug 
release occurs mainly by diffusion through polymer 
matrix from a region of high concentration to lower 
concentration.  
 
 
Figure 1: CPR versus time graph for both the 
formulations
 
Table 4: In-vitro release kinetic models 
Fabrication code Correlation coefficient (r
2
 value) 
Zero order First order Higuchi model Peppas model 
F1 0.841 0.696 0.876 0.821 
F2 0.971 0.718 0.982 0.962 
 
CONCLUSION: 
The current study exposed that ionotropic gelation 
technique can be effectively used for fabrication of 
Etodolac microbeads. Assortment of polymer is 
important to attain extra entrapment efficiency and to 
sustain the release of drug from beads. Guar gum 
blended microbeads showed more entrapment efficiency 
as well as more sustained release of drug. Also the 
formulation containing guar gum was found to be freer 
flowing. Therefore guar gum is moderately improved 
polymer of choice for Etodolac when compared to a 
formulation without guar gum. Guar gum can also be 
used for texture and clarity and also as a binder and 
excipient. 
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